Home/Pipeline/SLX-100

SLX-100

Oncology (specific indication undisclosed)

Phase 2Active

Key Facts

Indication
Oncology (specific indication undisclosed)
Phase
Phase 2
Status
Active
Company

About Lotus Pharmaceuticals

Taiwan‑based specialty pharma delivering oncology‑focused generics, biosimilars and NCEs across 90+ markets.

View full company profile

Therapeutic Areas